Zydus receives approval from DCGI for Saroglitazar Magnesium for treatment of Type II Diabetes

▴ Zydus
Zydus’ Saroglitazar Magnesium has been approved for the treatment of diabetes mellitus type 2 by the Drug Controller General of India

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has received the approval from the Drug Controller General of India for use of Saroglitazar Mg in the treatment of Type II Diabetes Mellitus as an add on therapy with Metformin. The drug was previously approved in the year 2013 for the treatment of ypertriglyceridemia and Diabetic Dyslipidemia in India. More than 1 Million patients are being treated with LipaglynTM.

The Diabetes Phase 3 clinical trial was a Multi-centric, Prospective, Randomized, Double- blind Study to Evaluate the Safety and Efficacy of Saroglitazar Mg 2 mg and 4 mg as compared to Pioglitazone 30 mg in patients with type 2 diabetes. The Phase 3 trial conducted in 1140 type 2 diabetes patients for a total of 56 weeks met the primary end-points (CTRI/2015/09/006203). The primary outcome measure was the change from baseline in glycosylated hemoglobin (HbA1c) for Saroglitazar 4 mg, 2 mg and Pioglitazone 30 mg at 24 weeks. The secondary outcome measures hange from baseline in fasting plasma glucose, 2 hour postprandial plasma glucose, lipid profile, Triglyceride (TG) cholesterol, Low density lipoprotein (LDL) cholesterol, Very low density lipoprotein (VLDL) cholesterol, High density lipoprotein (LDL) cholesterol, Total cholesterol (TC) cholesterol, Non HDL cholesterol, Apolipoprotein (Apo) A1 and Apo B between Saroglitazar (4 mg, 2 mg) and Pioglitazone (30 mg) treatment at Week 12, 24 and 56.

In Phase III diabetes trial, at 24 weeks, HbA1c was reduced by 1.38 g/dL with Saroglitazar 2 mg, 1.47 g/dL with Saroglitazar 4 mg and 1.41 g/dL with Pioglitazone 30 mg. At 56 weeks, HbA1c reduced by 1.34 g/dL with Saroglitazar 2 mg, 1.49 g/dL with Saroglitazar 4 mg and 1.47 g/dL with Pioglitazone 30 mg. Saroglitazar did not cause ypoglycemia or weight gain in this trial.

“Insulin resistance is one of the primary causes of diabetes and there is a huge unmet medical need for a safe and effective insulin sensitizer. Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from Type 2 diabetes mellitus. With the increasing cases of diabetes in India, the need to strengthen diabetes management and help patients control their blood sugar levels is of critical importance.” mentioned Pankaj Patel, Chairman, Zydus Group.

Saroglitazar (Lipaglyn™), is a novel PPARα/γ agonist having predominant PPAR alpha activity. The recommended dose of Lipaglyn™ is 4 mg once-a-day. Lipaglyn™ is a prescription drug and should be taken under guidance of a registered medical practitioner. Lipalgyn™ was first launched in India during September 2013. Over the last several years, more than 1 Million patients have been treated with Lipaglyn™ in India for management of Hypertriglyceridemia and Diabetic Dyslipidemia, and data has been presented at several scientific and medical conferences.

Tags : #Zydus #Type2diabetes #Drug #Controller #General #India #Medicircle

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Walking 30 Minutes a Day: A Simple Proven Solution to Lower Back Pain RecurrenceJune 22, 2024
Tragic Illicit Liquor Incident in Kallakurichi: Rising Deaths Prompt Swift Government ActionJune 22, 2024
Gleneagles Hospital Kengeri Launches South India's First 5G-Enabled Ambulance Service in Partnership with MedulanceJune 21, 2024
Asaya's Mission to Redefine Skincare for Melanin-Rich Individuals Gains MomentumJune 21, 2024
Alyve Health Gains $5.5 Million Funding to Expand and Innovate Health TechJune 21, 2024
Mobile-health Network Solutions [MaNaDr] to Offer GLP-1 Injectables for Medical Weight Loss from USD10/DayJune 20, 2024
Understanding Hemophilia: The Hidden Disorder Affecting Many in IndiaJune 20, 2024
Reducing the Risk of Childbirth Injuries: The Role of Lateral EpisiotomyJune 20, 2024
New Study Reveals How Menopause Affects Kidney Function and Dental HealthJune 20, 2024
Alka Yagnik Opens Up About Rare Hearing Loss and Importance of Hearing HealthJune 20, 2024
Severe Heatwave Grips Delhi: Over 19 Deaths Reported Amid Sweltering TemperaturesJune 20, 2024
Healthy Living at the Grassroots: PM Modi's Holistic Approach with Yoga and MilletsJune 20, 2024
A First-of-its-Kind Landmark Minimally Invasive Heart Surgery Saves Dog in IndiaJune 20, 2024
Japan Battles Surge in Deadly Streptococcal Toxic Shock Syndrome CasesJune 20, 2024
HRS Navigation announces aggressive hiring plans for its R&D and Clinical Support teamsJune 19, 2024
Vikram Solar Wins 393.9 MWp Module Supply Order for NLC India’s Khavda Solar ProjectJune 18, 2024
AIMS Organizes Blood Donation Camp on World Blood Donor DayJune 17, 2024
Preparing for the Future: FDA's New COVID-19 Vaccine Recommendation Focuses on KP.2June 17, 2024
From Pap Tests to HPV Screening: A New Era in Cervical Cancer PreventionJune 17, 2024
HR Conclave Focusing on Future-Forward Engineering heldJune 15, 2024